Epitalon vs Pinealon: Which Is Better for Sleep?
Should I take epitalon or pinealon for sleep?
Epitalon, if sleep is the question. It scores sleep quality 6.5 against pinealon's 1.7, because it acts on the pineal gland and melatonin output while pinealon is a neuroprotective peptide with no circadian mechanism. Pinealon wins the cognitive rows and costs a fraction as much. Both carry low confidence and gray-market access.
- Sleep quality is 6.5 against 1.7 and it is not close. Epitalon acts on pineal melatonin output. Pinealon has no circadian pathway at all, so the popular sleep query has a clear answer.
- Epitalon also wins longevity 6.5 to 1.8, geriatric 6.5 to 2.1 and healthspan 5.5 to 1.8, which is the whole reason its overall score is 6.7 against 6.4.
- Pinealon wins every cognitive row: cognition 2.5 to 2.0, memory 2.0 to 1.5, neuroplasticity 2.2 to 1.5, reaction time 2.0 to 1.0. All are low numbers on both sides.
- The cost gap is the largest in this batch. Pinealon runs $10 to $15 a month at its only PMID-anchored dose. Epitalon runs $95 to $1,100 per cycle, once or twice a year.
- Epitalon's cancer question is specific rather than vague. Al-dulaimi 2025 extended telomeres in normal cells and also activated alternative lengthening of telomeres in cancer cells.
- Neither has a controlled human trial. Pinealon's best human data is Meshchaninov 2015, an uncontrolled cohort of 32, and it reported a prooxidant signal and lower CD34 progenitor markers inside that cohort.
- Both are gray market with no approved product outside Russia and the CIS. Third-party certificate of analysis, sterility and cold chain are mandatory, not optional.
At a Glance
Epitalon
- Efficacy 3.3
- Breadth 3.2
- Evidence 3.4
- Speed 2.0
- Durability 3.2
- Bioindividuality 3.4
- Safety Risk 1.7
- Side Effects 1.5
- Cost 2.4
- Effort 2.3
- Opportunity Cost 2.2
- Dependency 1.3
- Reversibility 1.4
- Sleep Quality
- Longevity
- Circadian Rhythm
- Geriatric
AEDG tetrapeptide, pineal and telomerase bioregulator. BioHarmony 6.7, worth trying.
Pinealon (Glu-Asp-Arg)
- Efficacy 3.4
- Breadth 2.8
- Evidence 3.2
- Speed 3.0
- Durability 2.6
- Bioindividuality 3.0
- Safety Risk 1.6
- Side Effects 1.6
- Cost 2.6
- Effort 3.2
- Opportunity Cost 2.4
- Dependency 1.6
- Reversibility 1.6
- Neuroprotection
- Cognition Focus
- Neuroplasticity
- Antioxidant
EDR tripeptide, neuroprotective bioregulator. BioHarmony 6.4, worth trying.
Head-to-Head Verdict
| Use Case | Winner | Rationale |
|---|---|---|
| Sleep Quality | Epitalon | Epitalon 6.5 against pinealon's 1.7, the question most people arrive with. Epitalon's proposed mechanism includes restoring pineal melatonin output and circadian entrainment, and Korkushko 2004 studied epithalamin, its precursor preparation, on the circadian rhythm of melatonin-producing function in elderly people. Pinealon's name suggests an action its mechanism does not have. |
| Longevity | Epitalon | Epitalon 6.5 against 1.8, on the deepest animal record either side holds. Khavinson 2000 reported an 11 to 16% mean lifespan increase in Drosophila, and Anisimov 2003 supported tumor incidence and maximum-lifespan findings in female SHR mice without clear mean lifespan extension. Pinealon has no lifespan work in any species. Neither has human longitudinal data. |
| Geriatric | Epitalon | Epitalon 6.5 against pinealon's 2.1, and this is where the two products diverge in intent. Epitalon is positioned as a whole-organism geroprotector with subratings above 5.5 on longevity, healthspan and sleep. Kozina 2007 supports antioxidant-system effects of pineal geroprotective peptides in old rats. Pinealon is a neuron-level compound, and its 2.1 reflects that scope. |
| Healthspan | Epitalon | Epitalon 5.5 against 1.8. Its healthspan case rests on the SHR mouse tumor and survival data plus the in vitro telomere work, which is a mechanism chain rather than an outcome. Pinealon's only human data, Meshchaninov 2015, reported improved adaptive capacity and slowed biological-age markers in 32 polymorbid patients with no control group and soft endpoints. |
| Antioxidant | Epitalon | Epitalon 4.0 against pinealon's 2.2, with a caveat that applies to both. Kozina 2008 examined four short peptides and found no direct antioxidant activity, concluding they restrict lipoprotein lipid peroxidation indirectly by modifying structure. So neither is a radical scavenger. Epitalon wins on the strength of the old-rat antioxidant-system data in Kozina 2007. |
| Cognition Focus | Pinealon (Glu-Asp-Arg) | Pinealon 2.5 against epitalon's 2.0, the first of four cognitive rows the lower-scoring peptide takes. Nazimko 2012 gave railway workers 100 micrograms orally twice daily for two weeks and reported improved biological-age and adaptive-reaction indicators. That is an uncontrolled occupational cohort with soft endpoints, and it is also the only PMID-anchored human dose either compound has. |
| Memory | Pinealon (Glu-Asp-Arg) | Pinealon 2.0 against epitalon's 1.5. Mendzheritski 2013 found pinealon had a more pronounced positive effect on Morris-maze learning than cortexin in young and old rats, and Arutjunyan 2012 improved offspring spatial learning in methionine-loaded pregnant rats. Rodent models from the originating lab lineage, and still more than epitalon has here. |
| Neuroplasticity | Pinealon (Glu-Asp-Arg) | Pinealon 2.2 against 1.5, on the most modern study on this page. Kraskovskaya 2024 found EDR reduced oxidative DNA damage in aged human-derived induced neurons and, with related peptides, promoted dendritic branching, while finding no effect on mitochondrial or lysosomal activity. In vitro in human-derived cells, which is a step up from a rat and short of a person. |
| Reaction Time | Pinealon (Glu-Asp-Arg) | Pinealon 2.0 against epitalon's 1.0. This comes from the occupational cohorts: Nazimko 2012 in railway workers and Bashkireva 2012 comparing 150 lorry drivers with 150 metal craftsmen. Read the second one carefully. Its best result came from combined pinealon and vezugen, so it does not isolate pinealon at all. |
| Neuroprotection | Tie | Both 2.5, an exact tie, and they get there by different routes. Pinealon's case is direct: Khavinson 2011 showed dose-dependent restriction of reactive oxygen species and reduced necrotic cell death in cultured neurons under oxidative stress. Epitalon's runs through AEDG gene expression during neurogenesis (Khavinson 2020). Both are cell-culture findings from the originating lab. |
| Stress Resilience | Tie | Both 2.0. Neither has a stress trial and neither has a stress mechanism worth naming. Pinealon's occupational-cohort data touches adaptive capacity in a general way, and epitalon's touches circadian regulation, which is adjacent to stress physiology without testing it. Two floor-adjacent scores that should not decide a purchase. |
| Mood | Tie | Epitalon 2.0 against pinealon's 1.9, inside the noise. Pinealon has the more specific mechanism claim: Khavinson 2014 found EDR with KED stimulated serotonin expression in aging brain-cortex cell cultures with a docking-predicted binding site in the tryptophan hydroxylase gene. A docking prediction in cell culture is not a mood effect. |
Cost Comparison
| Intervention | Monthly Cost | Notes |
|---|---|---|
| Epitalon | $95 to $1,100 per cycle | ESTIMATE, priced 2026-09-08, research-chemical channel. Ten milligram vials run about $19 each in a ten-pack up to $55 singly. A 10-day course at 5 mg/day needs 5 vials, $95 to $275. A 20-day course at 10 mg/day needs 20 vials, $381 to $1,100. The Russian-style protocol runs once or twice a year rather than continuously, which is the only reason the annual figure is survivable. |
| Pinealon | $10 to $15 | ESTIMATE, priced 2026-09-08, research-chemical channel. A 20 mg vial is listed around $68, about $3.40 per milligram, and the only PMID-anchored dose is 100 micrograms per day, which is 3 mg a month, roughly $10 rising to about $15 with reconstitution supplies. Note that dose came from an oral study, and oral against injectable bioequivalence is unestablished. |
| The difference | Roughly 10x to 70x per course, in pinealon's favor | This is the largest cost gap between any two compounds in this batch, and it is a dose gap rather than a pricing gap. Epitalon is dosed in milligrams and pinealon in micrograms, so the same vial economics produce a $95 to $1,100 course against $10 to $15 a month.What that buys is not equivalent either. Epitalon's high end funds a 20-day, 10 mg/day cycle drawn from Russian clinical practice. Pinealon's $10 funds the single published oral human dose. Neither price includes the third-party certificate of analysis, sterility testing and cold-chain handling both reports require. |
When to Switch
Both carry a three-week assessment window, so the calendar is the same even though the protocols are not. Epitalon shows a first change at about seven days and full effect at twenty, which matches the 20-day Russian-style course. Pinealon shows a first change at about one week and full effect at two, and both of its figures are marked estimated rather than extracted.
Switch from pinealon to epitalon when the actual complaint is sleep, circadian disruption or general aging rather than cognition. Pinealon scores 1.7 on sleep quality and 1.8 on both healthspan and longevity, so there was never a mechanism there to wait for, and its name misleads on exactly this point: it is a neuroprotective tripeptide, not a pineal hormone tool.
Switch the other way, from epitalon to pinealon, when the target is memory, reaction time or focus, where pinealon leads every row, or when the epitalon course cost stops making sense against subratings this uncertain.
There is a stronger reason to leave epitalon than cost. Al-dulaimi 2025 found epitalon extended telomeres in normal epithelial and fibroblast cells and also activated alternative lengthening of telomeres in cancer cells.
That is an in vitro finding, not a clinical one, and it is why active malignancy, cancer history, known precancerous lesions and high hereditary cancer risk are all on its contraindication list.
Pinealon excludes active or suspected cancer too, without the telomerase mechanism behind it. Do not run both: the Bashkireva 2012 combined-peptide result is exactly the confounding this creates, and neither report has human safety data to fall back on.
Who Should Pick What?
Older adult whose main complaint is poor sleep and a shifted body clock
Epitalon
Sleep quality 6.5 against 1.7. Korkushko 2004 studied epithalamin, the precursor preparation, on the circadian rhythm of melatonin-producing function in elderly people, which is the closest human evidence on this page to the question being asked. Try melatonin first: it is cheaper, oral, approved and far better studied.
Someone buying a general anti-aging peptide course once a year
Epitalon
Longevity 6.5, geriatric 6.5, healthspan 5.5, against 1.8 to 2.1 on pinealon. The animal record is real: Drosophila lifespan in Khavinson 2000 and tumor incidence plus maximum lifespan in SHR mice in Anisimov 2003. The human record is not. Budget $95 to $1,100 per course and treat it as an experiment.
Anyone with a cancer history, precancerous lesions or high hereditary risk
Pinealon (Glu-Asp-Arg)
Epitalon is out. Its whole mechanism is telomerase induction, and Al-dulaimi 2025 showed it also activates alternative lengthening of telomeres in cancer cells. All four cancer-related exclusions are on its contraindication list. Pinealon still excludes active or suspected cancer, so this is a narrower answer rather than a safe one.
Person mainly interested in memory or mental sharpness
Pinealon (Glu-Asp-Arg)
It wins every cognitive row: cognition 2.5 to 2.0, memory 2.0 to 1.5, neuroplasticity 2.2 to 1.5, reaction time 2.0 to 1.0. Note what those numbers are. Its own contraindication list includes wanting an evidence-backed cognitive intervention, which is the report telling you the honest answer directly.
Anyone on a tight budget testing one of these
Pinealon (Glu-Asp-Arg)
$10 to $15 a month against $95 to $1,100 per epitalon course. The gap comes from dosing in micrograms rather than milligrams. Use the published dose, 100 micrograms, and know that Nazimko 2012 gave it orally, so an injectable protocol at that dose is extrapolating the route as well.
Competing athlete in a tested sport
Tie
Neither. Drug-tested athletic competition is on epitalon's contraindication list explicitly, and WADA's own framing puts non-approved pharmacological substances at S0 risk, which covers both of these. A gray-market vial with no verified contents makes a positive test harder to explain, not easier.
Anyone who cannot arrange third-party testing, sterility and cold chain
Tie
Neither, and this is a practical exclusion rather than a medical one. Both are gray market with purity verification required, and epitalon is an injectable peptide, which adds sterility and cold-chain handling to the list. Pinealon's oral route lowers the sterility bar and does nothing for identity or purity.
Someone who wants a peptide with actual clinical trial evidence
Tie
Neither, and both source reports say so at low confidence. Pinealon's best human data is Meshchaninov 2015, an uncontrolled cohort of 32 that also reported a prooxidant signal and lower CD34 blood-progenitor markers inside the same cohort. Epitalon's human evidence is precursor-preparation work that no independent group has replicated. No registered trial exists for either.
Research Highlights
-
Mechanism Difference
The names mislead here, so start with what each peptide actually is. Epitalon is a synthetic Ala-Glu-Asp-Gly tetrapeptide proposed to bind DNA promoter regions, induce telomerase, elongate telomeres in cultured cells, and restore pineal melatonin output and circadian rhythm. That last arm is why it scores 6.5 on sleep quality.Pinealon is a Glu-Asp-Arg tripeptide proposed to limit reactive oxygen species accumulation and neuronal death. Despite the name, it has no circadian or melatonin pathway, which is why it scores 1.7 on sleep. Its originating lab claims nuclear entry and gene regulation, and independent biophysics (Silanteva 2019) confirms only that the tripeptide can contact DNA.
-
Safety Comparison
Epitalon carries the more specific concern and it follows directly from its mechanism. Al-dulaimi 2025 found it extended telomeres in normal epithelial and fibroblast cells and also activated alternative lengthening of telomeres in cancer cells.Active malignancy, cancer history, known precancerous lesions and high hereditary cancer risk are all contraindicated, and FDA lists it among nominated compounding substances that may present safety risks.Pinealon's concerns are quieter and not absent. Its only human cohort (Meshchaninov 2015, n=32, uncontrolled) reported a prooxidant signal and lower CD34 blood-progenitor markers alongside its positive findings. Active or suspected cancer is contraindicated. Downside totals are 0.797 for epitalon against 0.974 for pinealon.
-
Cost Comparison
Pinealon runs about $10 to $15 a month at its only PMID-anchored dose of 100 micrograms per day, from a 20 mg vial listed around $68. Epitalon runs $95 to $275 for a 10-day 5 mg/day course and $381 to $1,100 for a 20-day 10 mg/day course, taken once or twice a year. Both are September 2026 research-chemical estimates.The gap is dosing, not markup: milligrams against micrograms of comparably priced material. Neither figure includes the third-party certificate of analysis both reports require, and epitalon's injectable route adds sterility and cold-chain handling on top.
-
Editorial Verdict
Epitalon scores 6.7 and pinealon 6.4, and the difference is which end of the body each one targets. Take epitalon for sleep, circadian rhythm and general aging, where it scores 6.5, 6.5 and 5.5 against pinealon's 1.7 and 1.8. Take pinealon for cognition, memory, plasticity and reaction time, where it leads every row at 2.0 to 2.5.Read those cognitive numbers honestly. Pinealon wins four rows and none of its winning scores clears 2.5, and its own contraindication list names wanting an evidence-backed cognitive intervention. Both source reports carry low confidence, neither compound has a controlled human trial, and both are gray market.
-
Durability
Epitalon holds the higher durability score, 3.2 against pinealon's 2.6, and the reason is protocol design rather than measurement. Epitalon is dosed as a course once or twice a year on the premise that the effect persists between cycles, which is the Russian-style clinical protocol its dose field references.Nothing has tested that premise in a controlled human study. Both assessment windows are three weeks. Epitalon's first noticeable change lands at about seven days and full effect at twenty, matching the course length. Pinealon's one week and two week figures are both marked estimated rather than extracted from data.
Frequently Asked Questions
- Which is better for sleep, epitalon or pinealon?
- Epitalon, and the gap is 6.5 against 1.7. Epitalon's proposed mechanism includes restoring pineal melatonin output and circadian entrainment, and Korkushko 2004 studied its precursor preparation on melatonin rhythm in elderly people. Pinealon has no circadian pathway despite the name. Try plain melatonin first: cheaper, oral, approved and vastly better studied.
- Is pinealon a pineal gland peptide?
- Not functionally. It is a Glu-Asp-Arg tripeptide from the Khavinson bioregulator program, proposed to limit reactive oxygen species and neuronal death. Its scores show it: sleep quality 1.7 against epitalon's 6.5. The name comes from the program lineage rather than from a melatonin or circadian mechanism.
- Does epitalon actually lengthen telomeres?
- In cultured cells, the evidence says yes. Khavinson 2003 reported telomerase activity and telomere elongation in human somatic cells, and Al-dulaimi 2025 independently replicated telomere extension in normal epithelial and fibroblast lines. No human study has measured telomere length after taking it. The same 2025 paper also found ALT activation in cancer cells.
- Why is epitalon so much more expensive?
- Dosing units, not markup. Epitalon is dosed at 5 to 10 mg/day and pinealon at 100 micrograms, and the vials cost roughly comparable amounts per milligram. A 20-day epitalon course at 10 mg/day needs 20 vials, $381 to $1,100. Pinealon's published dose costs about $10 to $15 a month.
- Is there any real human evidence for either one?
- Very little, and none of it controlled. Pinealon's best is Meshchaninov 2015, an uncontrolled cohort of 32 polymorbid patients with soft endpoints that also reported a prooxidant signal and lower CD34 progenitor markers. Epitalon's human data is precursor-preparation work like Korkushko 2004. No registered trial exists for either compound anywhere.
- Can I take both together?
- Do not, and there is a specific reason beyond the usual one. Bashkireva 2012 is exactly what combined peptide use produces: its best result came from pinealon plus vezugen together, so it cannot say what pinealon did. Running two gray-market peptides at once makes both your benefit and any adverse event unattributable.
- Which one is safer?
- Their downside totals are close, 0.797 for epitalon against 0.974 for pinealon, and their risks are different in kind. Epitalon's is specific: telomerase induction with demonstrated ALT activation in cancer cells, making any cancer history a hard exclusion. Pinealon's is the unknown of an unvalidated compound plus the prooxidant signal in its own small human cohort.
- Should I take pinealon orally or inject it?
- The only PMID-anchored human dose, Nazimko 2012, was oral at 100 micrograms twice daily. Its own report states oral and injectable bioequivalence is unestablished, so injecting means extrapolating both the route and the dose from a single uncontrolled occupational cohort. Oral at least matches the one study that exists.
Evidence Sources
- Preclinical Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (2025) Independent in vitro study. Telomere extension in normal epithelial and fibroblast cells, plus alternative lengthening of telomeres activation in cancer cells.
- Correction Correction to: Epitalon increases telomere length in human cell lines (2026) Correction notice replacing incorrect figures in the 2025 Biogerontology paper.
- Preclinical Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells (2003) In vitro human fetal fibroblast telomerase and telomere finding. Not human clinical evidence.
- Preclinical Effect of Epitalon on the lifespan increase in Drosophila melanogaster (2000) 11 to 16% mean lifespan increase in flies.
- Preclinical Effect of the peptide Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice (2003) Supports tumor incidence and maximum or last-survivor lifespan findings, without clear mean lifespan extension.
- Observational Effect of peptide preparation Epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people (2004) Melatonin circadian evidence for the epithalamin precursor preparation. Not a clean synthetic epitalon RCT.
- Preclinical Antioxidant properties of geroprotective peptides of the pineal gland (2007) Antioxidant-system evidence in old rats for pineal geroprotective peptides.
- Preclinical AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis (2020) Gene-expression and protein-synthesis mechanism paper proposing an epigenetic route.
- Preclinical Melting of DNA double strand after binding to geroprotective tetrapeptide (2008) Mechanistic DNA-binding context for geroprotective tetrapeptides.
- Regulatory FDA: safety risks associated with certain bulk drug substances nominated for use in compounding (2024) Lists epitalon among substances that may present compounding safety risks.
- Regulatory WADA: what is prohibited (2026) Non-approved pharmacological substances carry S0 risk for tested athletes, which covers both peptides on this page.
- Observational Meshchaninov 2015, Advances in Gerontology: open-label human cohort of 32 polymorbid patients on pinealon (2015) Improved adaptive capacity and slowed biological-age markers, alongside a prooxidant signal and lower CD34 blood-progenitor markers. Uncontrolled, soft endpoints.
- Preclinical Silanteva 2019, Journal of Physical Chemistry B: EDR tripeptide and DNA interaction (2019) Independent biophysics showing EDR can partly enter the DNA major groove and contact guanine, with magnesium promoting the interaction. Does not show in vivo gene regulation.
- Preclinical Khavinson 2011, Rejuvenation Research: pinealon in cultured neurons under oxidative stress (2011) Dose-dependent restriction of reactive oxygen species accumulation and reduced necrotic cell death.
- Preclinical Kraskovskaya 2024, International Journal of Molecular Sciences: EDR in aged human-derived induced neurons (2024) Reduced oxidative DNA damage and, with related peptides, promoted dendritic branching. No effect on mitochondrial or lysosomal activity.
- Observational Nazimko 2012, Advances in Gerontology: occupational cohort of railway workers on oral pinealon (2012) 100 micrograms orally twice daily for two weeks improved biological-age and adaptive-reaction indicators. Uncontrolled, and the only PMID-anchored human dose.
- Observational Bashkireva 2012, Advances in Gerontology: 150 lorry drivers and 150 metal craftsmen on bioregulating peptides (2012) Improved psychoemotional indices, with the best effect from combined pinealon and vezugen. Does not isolate pinealon.
- Preclinical Mendzheritski 2013, Advances in Gerontology: pinealon versus cortexin on Morris-maze learning (2013) More pronounced positive effect on maze learning than cortexin in young and old rats.
- Preclinical Arutjunyan 2012, International Journal of Clinical and Experimental Medicine: pinealon in methionine-loaded pregnant rats (2012) Improved offspring spatial learning and reduced cerebellar-neuron reactive oxygen species and necrotic cell counts.
- Preclinical Kozina 2008, Advances in Gerontology: antioxidant activity of four short peptides (2008) No direct antioxidant activity. Lipoprotein lipid peroxidation was restricted indirectly through structural modification.
- Preclinical Khavinson 2014, Bulletin of Experimental Biology and Medicine: EDR and serotonin expression (2014) EDR with KED stimulated serotonin expression in aging brain-cortex cell cultures, with a docking-predicted tryptophan hydroxylase binding site.
Glossary
Quick reference for the medical and technical terms used in this comparison.
- AEDG Ala-Glu-Asp-Gly
- The four amino acids making up epitalon. The sequence is the compound, and it is what the Khavinson bioregulator literature refers to when it says AEDG peptide.
- EDR Glu-Asp-Arg
- The three amino acids making up pinealon. Silanteva 2019 independently showed this tripeptide can contact DNA in the major groove, which is the one non-originating-lab mechanistic confirmation it has.
- TERT Telomerase Reverse Transcriptase
- The enzyme that rebuilds telomeres. Epitalon is proposed to induce it, which is both its longevity case and the source of its cancer contraindications.
- ALT Alternative Lengthening of Telomeres
- A telomerase-independent route cancer cells use to keep dividing. Al-dulaimi 2025 found epitalon activated it in cancer cell lines, which is the specific finding behind its cancer exclusions.
- Bioregulator Khavinson Peptide Bioregulator
- The Russian research program of short peptides claimed to regulate gene expression tissue by tissue. Both compounds on this page come from it, and most of their evidence comes from the originating lab.
- CD34 CD34 Blood Progenitor Marker
- A marker of circulating stem and progenitor cells. Meshchaninov 2015 reported it falling in the same cohort where pinealon's positive findings appeared, which is why that study cuts both ways.
- SHR mice Swiss-Derived SHR Mice
- The mouse strain used in Anisimov 2003, which supported tumor incidence and maximum-lifespan findings for epitalon without clear mean lifespan extension.
- S0 WADA Prohibited List Section S0
- Non-approved substances: anything with no current approval for human therapeutic use is prohibited at all times. It is the category that catches gray-market peptides like these two.
